Human adipose tissue-derived multipotent stem cells differentiate in vitro and in vivo into osteocyte-like cells

Biochem Biophys Res Commun. 2007 Sep 21;361(2):342-8. doi: 10.1016/j.bbrc.2007.06.180. Epub 2007 Jul 20.

Abstract

Cell-based therapies are used to treat bone defects. We recently described that human multipotent adipose-derived stem (hMADS) cells, which exhibit a normal karyotype, self renewal, and the maintenance of their differentiation properties, are able to differentiate into different lineages. Herein, we show that hMADS cells can differentiate into osteocyte-like cells. In the presence of a low amount of serum and EGF, hMADS cells express specific molecular markers, among which alkaline phosphatase, CBFA-1, osteocalcin, DMP1, PHEX, and podoplanin and develop functional gap-junctions. When loaded on a hardening injectable bone substitute (HIBS) biomaterial and injected subcutaneously into nude mice, hMADS cells develop mineralized woven bone 4 weeks after implantation. Thus hMADS cells represent a valuable tool for pharmacological and biological studies of osteoblast differentiation in vitro and bone development in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / cytology*
  • Adipose Tissue / drug effects
  • Animals
  • Biomarkers / metabolism
  • Cell Differentiation* / drug effects
  • Child, Preschool
  • Choristoma
  • Culture Media
  • Epidermal Growth Factor / pharmacology
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Multipotent Stem Cells / cytology*
  • Multipotent Stem Cells / drug effects
  • Osteocytes / cytology*
  • Osteocytes / drug effects
  • Osteogenesis / drug effects

Substances

  • Biomarkers
  • Culture Media
  • Epidermal Growth Factor